Δημοσιεύσεις

Α/α

Δημοσιεύσεις σε Διεθνή Ιατρικά Περιοδικά

  1.  

Ch.A.Papadimitriou, G.Fountzilas, G.Aravantinos, Ch.Kalofonos, L.A.Moulopoulos, E.Briassoulis, D.Gika, M-A.Dimopoulos.

Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel pretreated, platinum-sensitive ovarian cancer patients.

Gynecol Oncol 92: 152-159, 2004.

  1.  

G.P.Stathopoulos, K.Syrigos, A.Polyzos, G.Fountzilas, S.K.Rigatos, N.Ziras, A.Potamiannou, I.Tsiakopoulos, N.Androulakis, G.Aravantinos, A.Athanasiadis, P.Papakotoulas, V.Georgoulias.

Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.

Ann Oncol 15: 224-229, 2004.

  1.  

G.Fountzilas, G.Stathopoulos, G.Kouvatseas, A.Polychronis, G.Klouvas, E.Samantas, N.Zamboglou, K.Kyriakou, A.Adamou, D.Pectasidis, Th.Ekonomopoulos, Ch.Kalofonos, D.Bafaloukos, V.Georgoulias, E.Razi, D.Koukouras, V.Zombolas, P.Kosmidis, D.Skarlos, N.Pavlidis. 

Adjuvant cytotoxic and endocrine therapy in pre- and post menopausal patients with breast cancer and 1-9 infiltrated nodes: 5 year results of HeCOG randomised HE 10/92 study.

Am J Clin Oncol 27: 57-67, 2004.

  1.  

E.Razis, P.Kosmidis, G.Aravantinos, C.Bacoyiannis, J.Janninis, H.Timotheadou, C.Christodoulou, G.Fountzilas.

Second line chemotherapy with 5-fluorouracil and vinorelbine in antracycline and taxane pretreated patients with metastatic breast cancer.

Cancer Invest Cancer Invest 22:10-15, 2004.

  1.  

E.Andreopoulou, D.Pectasides, M.A.Dimopoulos, C.Nicolaides, G.Fountzilas, S.Valsami, T.Economopoulos. Primary mediastinal large B cell lymphoma.

A clinical study of a distinct clinical entity and treatment outcome in 20 patients. A review of the literature.

Am J Clin Oncol 27: 312-316, 2004.

  1.  

A.Bamias, Ch.Deliveliotis, G.Fountzilas, D.Gika, A.Anagnostopoulos, M.P.Zorzou, E.Kastritis, C.Konstantindis, P.Kosmidis, M.A.Dimopoulos.

Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract. A study by the Hellenic Cooperative Oncology Group.

J Clin Oncol 22: 2150-2154, 2004.

  1.  

G.Fountzilas, C.Christodoulou, D.Tsavdaridis, A.Kalogera-Fountzila, G.Aravantinos, E.Razis, J.Kostopoulos, H.P.Kalofonos, P.Papakostas, M.Karina, H.Goga, D.Skarlos. 

Paclitaxel and gemcitabine, as first line chemotherapy, combined with trastuzumab in patients with advanced breast cancer.  

Cancer Investigation 22: 655-662, 2004.

  1.  

E.Razis, G.Fountzilas.

Continuation of trastuzumab beyond disease progression: more questions than answers. (Commentary).

Clin Breast Cancer 5: 59-62, 2004

  1.  

H.Gogas, D.Bafaloukos, G.Aravantinos, G.Fountzilas, D.Tsoutsos, P.Panagiotou, K.Frangia, H.P.Kalofonos, E.Briasoulis, O.Castana, A.Polyzos, D.Pectasides, J.Ioannovich.

Vinorelbine in combination with interleukin-2 as second line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology Group.

Cancer Invest 22: 832-839, 2004.

  1.  

A.G.Plataniotis, M-E. Theofanopoulou, A.Kalogera-Fountzila, A.A.Haritanti, E.Ciuleanou, N.Ghilezan, N.Zamboglou, A.Dimitriadis I.Sofroniadis, G.Fountzilas.

Prognostic impact of tumor volumetry in patients with locally advanced head and neck carcinomas (non-nasopharyngeal) treated either by radiotherapy alone or by combined radiochemotherapy in a randomized trial.

Int J Radiat Oncol Biol Phys 59: 1018-1026, 2004.

  1.  

G.Fountzilas, E.Ciuleanu, U.Dafni, G.Plataniotis, A.Kalogera-Fountzila, E.Samantas, E.Athanassiou, J.Tzitzikas, T.Ciuleanu, A.Nikolaou, P.Pantelakos, T.Zaraboukas, N.Zamboglou, J.Daniilidis, N.Ghilezan.

Concomitant radio-chemotherapy versus radiotherapy alone in patients with head and neck cancer A Hellenic Cooperative Oncology Group phase III study.

Med Oncol 21: 95-107, 2004.

  1.  

J.Janinis, G.P.Stathopoulos, P.Nikolaidis, H.P.Kalofonos, A.Kalogera-Fountzila, E.Samantas, G.Aravantinos, A.Anagnostopoulos, C.Tolis, T.Makatsoris, S.K.Rigatos, D.Bafaloukos, M.A.Dimopoulos, J.Daniilidis, G.Fountzilas.

Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG)

Anticancer Drugs 15: 479-487, 2004.

  1.  

H.Gogas, D.Bafaloukos, J.Ioannovich, D.Skarlos, A.Polyzos, G.Fountzilas, H.P. Kalofonos, G.Aravantinos, D.Tsoutsos, P.Panagiotou, K.Frangia, T.Petrakopoulou, D.Pectasides.

Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year. A Hellenic Cooperative Oncology Group Study.

Anticancer Res 24: 1947-1952, 2004.

  1.  

E.Giannoulis, K.Mandraveli, K.Giannoulis, C.Nikolaides, E.Zervou, E.Papageorgiou, D.Zoulias, A.Tourkantonis, T.Economopoulos, G.Fountzilas.

The prevalence of hepatitis C and hepatitis G virus infection in patients with non-Hodgkin lymphomas in Greece

Acta Hematol 112: 189-193, 2004.

  1.  

G.Fountzilas, H.P.Kalofonos, U.Dafni, C.Papadimitriou, D.Bafaloukos, P.Papakostas, A.Kalogera-Fountzila, H.Gogas, G.Aravantinos, L.A.Moulopoulos, T.Economopoulos, D.Pectasides, N.Maniadakis, V.Siafaka, E.Briasoulis, C.Christodoulou, D.Tsavdaridis, P.Makrantonakis, E.Razis, P.Kosmidis, D.Skarlos, M.A.Dimopoulos.

Paclitaxel and epirubicin versus paclitaxel and carboplatin, as first line chemotherapy, in patients with advanced breast cancer. A phase III study conducted by the Hellenic Cooperative Oncology Group.

 Ann Oncol 15:1517-26, 2004.

  1.  

G.Pentheroudakis, L.Kostadima, G.Fountzilas, A.Kalogera-Fountzila, G.Klouvas, C.Kalofonos, N.Pavlidis.

Cavitating squamous cell lung carcinoma-distinct entity or not? Analysis of radiological, histological and clinical features.

Lung Cancer 45: 349-355, 2004.

  1.  

D.Bafaloukos, D.Tsoutsos, G.Fountzilas, H.Linardou, C.Christodoulou, H.P.Kalophonos, E.Briassoulis, P.Panagiotou, H.Hatzichristou, H.Gogas.

The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma.

Melanoma Res 14: 289-294, 2004.

  1.  

E.Briasoulis, V.Karavasilis, L.Kostadima, M.Ignatiadis, G.Fountzilas, N.Pavlidis.

Metastatic breast cancer confined to the bones: Portrayal of a clinical entity.

Cancer 101:1524-1528, 2004.

  1.  

E.Briasoulis, G.Pentheroudakis, H.Timotheadou, D.Rammou, N.Pavlidis, G.Fountzilas.

Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: a phase I study.

Anticancer Drugs 15:747-52, 2004.

  1.  

D.Bafaloukos, C.Papadimitriou, H.Linardou, G.Aravantinos, P.Papakostas, D.Skarlos, P.Kosmidis, G.Fountzilas, H.Gogas, C.Kalofonos, A.M.Dimopoulos.

Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group.

Br J Cancer 91: 1639-1644, 2004.

  1.  

K.Giannoulis, G.Fountzilas, N.Angouridakis, C.Angouridaki, E.Giannoulis, O.Gamvros.

Serum levels of bcl-2 in patients with colorectal cancer.

Tech Coloproctol 8: 56-8, 2004.

  1.  

K.Giannoulis, C.Angouridaki, G.Fountzilas, C.Papapolychroniadis, E.Giannoulis, O.Gamvros.

Serum concentrations of soluble ICAM-1 and VCAM-1 in patients with colorectal cancer. Clinical implication.

Tech Coloproctol 8: s65-7, 2004.

  1.  

A.Bamias, K.Syrigos, G.Fountzilas, E.Tzamakou, K.Soulti, V.Karavasilis, Y.Alamanos, C.Christodoulou, N.Pavlidis. 

Intensified bimonthly cisplatin with bolus 5-fluorouracil, continuous 5-flouorouracil and high dose leucovorin (LV5FU2) in patients with advanced gastrointestinal carcinomas: a phase I dose-finding and pharmacokinetic study.

Am J Clin Oncol 27:465-471, 2004.

  1.  

TE.Ciuleanu, G.Fountzilas, E.Ciuleanu, M.Plataniotis, N.Todor, N.Ghilezan. 

Paclitaxel and carboplatin in relapsed or metastatic nasopharyngeal carcinoma: a multicenter phase II study.

J BUON 9(2):161-165, 2004.

  1.  

E.Razis, D.Skarlos, E.Briassoulis, M.A.Dimopoulos, G.Fountzilas, S.Lambropoulos, S.Rigatos, P.Kopteridis, H.Efstathiou, E.Tzamakou, C.Bakoyiannis, D.Pectasides, T. Makatsoris, G.Varthalitis, S.Papadopoulos, P.Kosmidis.

Treatment of non-small-cell lung cancer with gefinitib (‘Iressa’, ZD 1839): the Greek experience with a comparissionate – use programme

Anticancer Drugs 16: 191-198, 2005.

  1.  

A.Apessos, M. Mihalatos, I.Danielidis, G.Kallimanis, N.J.Agnantis, I.K.Triantafillidis, G.Fountzilas, P.A.Kosmidis, E.Razis, V.A.Georgoulias, HeCOG, HeHeGI, G. Nasioulas.

HMSH2 is the most commonly mutated MMR gene in a cohort of Greek HNPCC patients.

Br J Cancer 92: 396-404, 2005.

  1.  

T.Economopoulos, S.Papageorgiou, M.A.Dimopoulos, N.Pavlidis, C.Tsatalas, N.Zoumbos, A.Foudoulakis, D.Pectasides, D.Rontogianni, E.Rizos, P.Chalkia, A.Anagnostopoulou, M.Melachrinou, E.Kyriakou, E.Papageorgiou, G.Fountzilas.

Non-Hodgkin’s lymphomas in Greece according to the revised European- American/WHO classification of lymphoid neoplasms.

Acta Hematol 113: 97-103, 2005.

  1.  

K.Vlachtsis, A.Nikolaou, K.Markou, G.Fountzilas, I.Daniilidis.

Clinical and molecular prognostic factors in operable laryngeal cancer.

Eur Arch. Otorhinolaryngol 262: 890-898, 2005.

  1.  

V.Karavasilis, V.Malamou-Mitsi, E.Briasoulis, E.Tsanou, E.Kitsou, H.Kalofonos, G.Fountzilas, T.Fotsis, N.Pavlidis.

Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1.

BMC Cancer 5:25, 2005.

  1.  

G.Pentheroudakis, E.Briasoulis, V.Karavassilis, G.Fountzilas, N.Xeros, G.Samelis, E.Samantas, N.Pavlidis.

Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: Active, but how effective?

Acta Oncol 44(2):155-60, 2005.

  1.  

C.Karanikiotis, I.Skiadas, M.Karina, S.Georgakopoulou, E.Georgakopoulos, G.Fountzilas.

A novel chromatographic method for Ep-CAM mRNA detection in peripheral blood and bone marrow of patients with metastatic colorectal cancer.

Anticancer Res 25:319-24, 2005.

  1.  

G.Fountzilas, C.Tolis, A.Kalogera-Fountzila, C.Karanikiotis, M.Bai, D.Misailidou, E.Samantas, E.Athanassiou, D.Papamichael, P.Tsekeris, N.Katontritis, A.Nikolaou, G.Plataniotis, T.Makatsoris, P.Papakostas, N.Zamboglou, J.Daniilidis.

Induction chemotherapy with cisplatin, epirubicin and paclitaxel (CEP) followed by concomitant radiotherapy and weekly paclitaxel for the management of locally advanced nasopharyngeal carcinoma. A Hellenic Cooperative Oncology Group phase II study.

Strahlenther Onkol 181:223-230, 2005.

  1.  

D.Bafaloukos, D.Tsoutsos, H.Kalofonos, S.Chalkidou, P.Panagiotou, E.Linardou, E.Briassoulis, E.Efstathiou, A.Polyzos, G.Fountzilas, C.Christodoulou, C.Kouroussis, T.Iconomou, H.Gogas.

Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group.

Ann Oncol 16: 950-957, 2005.

  1.  

M.Mihalatos, A.Apessos, H.Dauwerse, V.Velissariou, A.Psychias, A.Koliopanos, K.Petropoulos, J.K.Triantafillidis, I.Danielidis, G.Fountzilas, N.J.Agnantis, G.Nasioulas.

Rare mutations predisposing to familial adenomatous polyposis in Greek FAP patients.

BMC Cancer 5:40, 2005.

  1.  

HP.Kalofonos, G.Aravantinos, P.Kosmidis, P.Papakostas, T.Economopoulos, M.Dimopoulos, D.Skarlos, A.Bamias, D.Pectasides, S.Chalkidou, M.Karina, A.Koutras, E.Samantas, C.Bacoyiannis, GF.Samelis, G.Basdanis, F.Kalfarentzos, G.Fountzilas.

Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study.

Ann Oncol 16: 869-877, 2005.

  1.  

D.Pectasides, G.Fountzilas, G.Aravantinos, H.P.Kalofonos, E.Efstathiou, E.Salamalekis, D.Farmakis, D.Skarlos, E.Briasoulis, T.Economopoulos, M.A.Dimopoulos.

Advanced stage mucinous epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience.

Gynecol Oncol 97: 436-41, 2005.

  1.  

T.Makatsoris, H.P.Kalofonos, G.Aravantinos, C.Papadimitriou, E.Kastritis, S.K. Rigatos, N.Xiros, T.Petsas, T.Economopoulos, A.K Sakadamis, G.Fountzilas.

A Phase II Study of Capecitabine plus Oxaliplatin (XELOX): a New First-Line Option in Metastatic Colorectal Cancer.

Int J Gastrointestinal Cancer 35, 103-109, 2005.

  1.  

G.Aravantinos, G.Fountzilas, P.Kosmidis, M.A.Dimopoulos, G.P.Stathopoulos, N.Pavlidis, D.Bafaloukos, C.Papadimitriou, S.Karpathios, V.Georgoulias, P.Papakostas, H.P.Kalofonos, E.Grimani, D.V.Skarlos.

Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study.

Ann Oncol 16:1116-1122, 2005.

  1.  

P.Bruzzi, L.Del Mastro, M.P.Sormani, L.Bastholt, M.Danova, C.Focan, G.Fountzilas, J.Paul, R.Rosso, M.Venturini.

Objective Response to Chemotherapy As a Potential Surrogate End Point of Survival in Metastatic Breast Cancer Patients.

J Clin Oncol 23: 5117-5125, 2005.

  1.  

E.Briasoulis, E.Samantas, H.Kalofonos, D.Skarlos, T.Makatsoris, C.Christodoulou, G.Fountzilas, A.Bamias, MA.Dimopoulos, P.Kosmidis, N.Pavlidis.

Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer.

Cancer Chemother Pharmacol 56: 521-528, 2005.

  1.  

G.Fountzilas, D.Pectasides, A.Kalogera-Fountzila, D.Skarlos, H.P.Kalofonos, C.Papadimitriou, D.Bafaloukos, S.Lambropoulos, S.Papadopoulos, H.Kourea, C.Markopoulos, H.Linardou, D.Mavroudis, E.Briasoulis, N.Pavlidis, E.Razis, P.Kosmidis, H.Gogas

Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group.

Br Cancer Res Treat 92: 1-9, 2005.

  1.  

E.Papageorgiou, P.Tsirigotis, M.Dimopoulos, N.Pavlidis, G.Fountzilas, S.Papageorgiou, T.Economopoulos.

Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma. A phase II trial by the Hellenic Cooperative Oncology Group (HeCOG).

Eur J Haematol 75: 124-129, 2005.

  1.  

D.V.Skarlos, H.P.Kalofonos, G.Fountzilas, M.A.Dimopoulos, N.Pavlidis, E.Razis, T.Economopoulos, D.Pectasides, H.Gogas, P.Kosmidis, D.Bafaloukos, G.Klouvas, G.Kyratzis, G.Aravantinos

Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/ refractory to platinum and/ or taxanes. A HeCOG Phase II Study.

Anticancer Res 25: 3103-3108, 2005.

  1.  

G.F.Samelis, H.Kalofonos, A.Adamou, P.Kosmides, D.Skarlos, G.Aravantinos, C.Kiamouris, O.Adimchi, G.Fountzilas, A.M.Dimopoulos.

The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.

Urology 66:382-5, 2005.

  1.  

D.Pectasides, G.Aravantinos, G.Fountzilas, C.Kalofonos, E.Efstathiou, M.Karina, N.Pavlidis, D.Farmakis, T. Economopoulos, M.A.Dimopoulos

Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature.

Anticancer Res 25: 3553-3558, 2005.

  1.  

Early Breast Cancer Trialist’s Collaborative Group (EBCTCG).

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. 

Lancet 365: 1687-1717, 2005.

  1.  

G.Fountzilas, C.Tolis, A.Kalogera-Fountzila, D.Misailidou, P.Tsekeris, M.Karina, A.Nicolaou, E.Samantas, T.Makatsoris, E.Athanassiou, D.Skarlos, A.Bamias, N.Zamboglou, T.Economopoulos, S.Karanastassi, N.Pavlidis, J.Daniilidis.

Paclitaxel, cisplatin, leucovorin and continuous infusion fluorouracil followed by concomitant chemo-radiotherapy for locally advanced non-nasopharyngeal squamous cell carcinoma of the head and neck. A Hellenic Cooperative Oncology Group phase II study.

Med Oncol 22: 269-279, 2005.

  1.  

G.Fountzilas, D.Skarlos, U.Dafni, H.Gogas, E.Briasoulis, D.Pectasides, C.Papadimitriou, C.Markopoulos, A.Polychronis, H.P.Kalofonos, V.Siafaka, P.Kosmidis, E.Timotheadou, D.Tsavdaridis, D.Bafaloukos, P.Papakostas, E.Razis, P.Makrantonakis, G.Aravantinos, C.Christodoulou, A.M.Dimopoulos.

Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.

Ann Oncol 16: 1762-1771, 2005.

  1.  

V.Karavasilis, V.Malamou-Mitsi, E.Briasoulis, E.Tsanou, E.Kitsou, H.Kalofonos, G.Fountzilas, T. Fotsis, N.Pavlidis.

Matrix metalloproteinases in carcinoma of unknown primary.

Cancer 104: 2282-2287, 2005.

  1.  

A.Bamias, G.Basdanis, I.Xanthakis, N.Pavlidis, G.Fountzilas.

Prognostic factors in patients with colorectal cancer receiving adjuvant chemotherapy or chemoradiotherapy: a pooled analysis of two randomized studies.

Int J Gastrointest Cancer 36:29-38, 2005.

  1.  

T.Economopoulos, S.Papageorgiou, D.Rontogianni, V.Kaloutsi, G.Fountzilas, C.Tsatalas, N. Pavlidis, D.Pectasides, E.Papageorgiou, M.Dimopoulos.

Multifocal extranodal non-Hodgkin lymphoma: a clinicopathologic study of 37 cases in Greece, a Hellenic Cooperative Oncology Group study.

Oncologist 10:734-738, 2005.

  1.  

E.Timotheadou, P.Papakostas, D.Tsavdaridis, G.Basdanis, H.Kalofonos, G.Aravantinos, D.Bafaloukos, G.Fountzilas.

 Irinotecan and oxaliplatin combination, as second line treatment, in fluoropyrimidine-pretreated advanced colorectal cancer. A phase II study by the Hellenic Cooperative Oncology Group (HeCOG).

Tumori 91:309-313, 2005.

  1.  

Early Breast Cancer Trialist’s Collaborative Group.

Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.

Lancet 366:2087-2106, 2005.

  1.  

D.Nitti, J.Wils, J.Guimaraes Dos Santos, G.Fountzilas, PF.Conte, C.Sava, A.Tres, RC.Coombes, D.Crivellari, A.Marchet, E.Sanchez, JM.Bliss, J.Homewood, ML.Couvreur, E.Hall, B.Baron, E.Woods, M.Emson, E.Van Cutsem, M.Lise.

Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG.

Ann Oncol 17: 262-269, 2006.

  1.  

M.Karthaus, A.Kretzschmar, H.Kroning, M.Biakhov, D.Irwin, N.Marschner, C.Slabber, G.Fountzilas, A.Garin, NG.Abecasis, W.Baronius, GG.Steger, T.Sudhoff, C.Giorgetti, P.Reichardt.

Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial.

Ann Oncol 17:289-296, 2006.

  1.  

G.Pentheroudakis, G.Fountzilas, D.Bafaloukos, V.Koutsoukou, D.Pectasides, D.Skarlos, E.Samantas, HP.Kalofonos, H.Gogas, N.Pavlidis.

Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.

Breast Cancer Res Treat 97: 237-244, 2006.

  1.  

A.Bamias, LA.Moulopoulos, A.Koutras, G.Aravantinos, G.Fountzilas, D.Pectasides, E.Kastritis, D.Gika, D.Skarlos, H.Linardou, HP.Kalofonos, MA.Dimopoulos. 

The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma.

Cancer 106:297-303, 2006.

  1.  

H.Gogas, J.Ioannovich, U.Dafni, C.Stavropoulou-Giokas, K.Frangia, D.Tsoutsos, P.Panagiotou, A.Polyzos, O.Papadopoulos, A.Stratigos, C.Markopoulos, D.Bafaloukos, D.Pectasides, G.Fountzilas, J.M.Kirkwood.

Prognostic Significance of the Appearance of Autoimmunity during Treatment of Melanoma with Interferon Alfa-2b.

N Engl J Med 354: 709-718, 2006.

  1.  

G.Pentheroudakis, K.Neanidis, L.Kostadima, G.Fountzilas, N.Pavlidis. 

Elderly patients with squamous lung carcinoma: faring better or worse?

Support Care Cancer 14 (8): 867-870, 2006.

  1.  

D.Pectasides, G.Fountzilas, G.Aravantinos, C.Kalofonos, H.Efstathiou, D.Farmakis, D.Skarlos, N.Pavlidis, T.Economopoulos, MA.Dimopoulos. 

Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.

Gynecol Oncol 102(2): 285-291, 2006.

  1.  

I.Kostopoulos, P.Arapantoni-Dadioti, H.Gogas, S.Papadopoulos, V.Malamou-Mitsi, CD.Scopa, S.Markaki, E.Karagianni, V.Kyriakou, A.Margariti, E.Kyrkou, K.Pavlakis, T.Zaramboukas, A.Skordalaki, A.Bourli, C.Markopoulos, D.Pectasides, MA.Dimopoulos, D.Skarlos, G.Fountzilas

Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.

Breast Cancer Res Treat 96(3): 251-261, 2006.

  1.  

P.Papakostas, D.Tsavdaridis, P.Kosmidis, HP.Kalofonos, A.Sakantamis, D.Janinis, D.Skarlos, D.Bafaloukos, A.Bamias, N.Xiros, G.Fountzilas.

Combination docetaxel (Taxotere), fluorouracil, and leucovorin (TFL), as first-line chemotherapy in advanced gastric cancer: a Hellenic Cooperative Oncology Group phase II study.

Gastric Cancer 9(1): 26-31, 2006.

  1.  

S.Murray, E.Timotheadou, H.Linardou, AV.Vrettou, I.Kostopoulos, J.Skrickova, C.Papakostantinou, C.Christodoulou, D.Pectasides, E.Samantas, P.Papakostas, DV.Skarlos, P.Kosmidis, G.Fountzilas.

Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients.

Lung Cancer 52(2): 225-33, 2006.

  1.  

HP.Kourea, AK.Koutras, V.Zolota, I.Grimani, E.Tzoracoeleftherakis, D.Koukouras, G.Fountzilas, H.Gogas, K.Kyriakou, A.Adamou, HP.Kalofonos.

Expression of p27KIP1, p21WAF1 and p53 does not correlate with prognosis in node-negative invasive ductal carcinoma of the breast.

Anticancer Res 26(2B):1657-1668, 2006.

  1.  

J.Cassidy, JY.Douillard, C.Twelves, JJ.McKendrick, W.Scheithauer, I.Bustova, PG.Johnston, K.Lesniewski-Kmak, S.Jelic, G.Fountzilas, F.Coxon, E.Diaz-Rubio, TS.Maughan, A.Malzyner, O.Bertetto, A.Beham, A.Figer, P.Dufour, KK.Patel, W.Cowell, LP.Garrison.

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.

Br J Cancer 94(8):1122-1129, 2006.

  1.  

A.Psyrri, G.Fountzilas.

Advances in the treatment of locally advanced non-nasopharyngeal squamous cell carcinoma of the head and neck region.

Med Oncol 23(1):1-15, 2006.

  1.  

G.Pentheroudakis, E.Razis, A.Athanassiadis, N.Pavlidis, G.Fountzilas.

Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety.

Med Oncol 23(2):147-60, 2006.

  1.  

A.Onyenadum, H.Gogas, P.Kosmidis, G.Aravantinos, D.Bafaloukos, H.Bacoyiannis, C.Markopoulos, A.Koutras, E.Tzorakoelefterakis, T.Makatsoris, G.Fountzilas, HP.Kalofonos, Hellenic Cooperative Oncology Group. 

Mitoxantrone plus gemcitabine in pretreated patients with metastatic breast cancer.

J Chemother 18(2):192-198, 2006.

  1.  

G.Fountzilas, P.Papakostas, U.Dafni, T.Makatsoris, M.Karina, A.Kalogera-Fountzila, N.Maniadakis, G.Aravantinos, K.Syrigos, A.Bamias, C.Christodoulou, T.Economopoulos, H.Kalofonos, A.Nikolaou, N.Angouridakis, G.Stathopoulos, D.Bafaloukos, N.Pavlidis, J.Daniilidis.

Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group.

Ann Oncol 17(10):1560-1567, 2006.

  1.  

L.Kostadima, G.Pentheroudakis, G.Fountzilas, M.Dimopoulos, D.Pectasides, H.Gogas, C.Christodoulou, E.Samantas, D.Bafaloukos, P.Arapantoni, H.Kalofonos, P.Papakostas, T.Economopoulos, A.Bamias, N.Pavlidis, U.Stropp, R.Wirtz, G.Hennig.

Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival.

Breast Cancer Res Treat 100(2):161-167, 2006.

  1.  

A.Psyrri, G.Fountzilas.

Can the standard chemotherapeutic regimen be improved upon for small-cell lung cancer?

Nat Clin Pract Oncol 3(7):360-361, 2006.

  1.  

D.Mauri, G.Pentheroudakis, D.Bafaloukos, D.Pectasides, E.Samantas, E.Efstathiou, HP.Kalofonos, K.Syrigos, G.Klouvas, P.Papakostas, P.Kosmidis, G.Fountzilas, N.Pavlidis; Hellenic Coopeprative Oncologic Group (HeCOG).

Non-small cell lung cancer in the young: a retrospective analysis of diagnosis, management and outcome data.

Anticancer Res 26(4B): 3175-3181, 2006.

  1.  

A.Kalogera-Fountzila, D.Karanikolas, N.Katodritis, E.Samantas, A.Sarafopoulos, I.Ikonomou, N.Zamboglou, N.Tselis, AS.Dimitriadis, G.Fountzilas, AJCC (American Joint Committee on Cancer). 

Prognostic factors and significance of the revised 6th edition of the AJCC classification in patients with locally advanced nasopharyngeal carcinoma.

Strahlenther Onkol 182(8):458-466, 2006.

  1.  

GP.Stathopoulos, K.Syrigos, G.Aravantinos, A.Polyzos, P.Papakotoulas, G.Fountzilas, A.Potamianou, N.Ziras, J.Boukovinas, J.Varthalitis, N.Androulakis, A.Kotsakis, G.Samonis, V.Georgoulias.

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.

Br J Cancer 95(5): 587-592, 2006.

  1.  

E.Razis, M.Karina, S.Karanastassi, G.Fountzilas.

Three case reports of hand-foot syndrome with gefitinib.

Cancer Invest 24(5): 514-516, 2006.

  1.  

V.Malamou-Mitsi, H.Gogas, U.Dafni, A.Bourli, T.Fillipidis, M.Sotiropoulou, D.Vlachodimitropoulos, S.Papadopoulos, O.Tzaida, G.Kafiri, V.Kyriakou, S.Markaki, I.Papaspyrou, E.Karagianni, K.Pavlakis, T.Toliou, C.Scopa, P.Papakostas, D.Bafaloukos, C.Christodoulou, G.Fountzilas.

Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.

Ann Oncol 17(10):1504-1511, 2006.

  1.  

H.Gogas, A.Polyzos, I.Stavrinidis, K.Frangia, D.Tsoutsos, P.Panagiotou, C.Markopoulos, O.Papadopoulos, D.Pectasides, M.Mantzourani, M.Middleton, G.Vaiopoulos, G.Fountzilas.

Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.

Ann Oncol 17(12):1835-1841, 2006.

  1.  

A.Bamias, C.Papadimitriou, E.Efstathiou, A.Rodolakis, G.Vlahos, Z.Voulgaris, G. Bozas, G.Fountzilas, G.Aravantinos, E.Razis, D.Gika, MA.Dimopoulos.

Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.

BMC Cancer. 6:228, 2006.

  1.  

G.Papaxoinis, S.Papageorgiou, D.Rontogianni, V.Kaloutsi, G.Fountzilas, N.Pavlidis, M.Dimopoulos, C.Tsatalas, N.Xiros, T.Economopoulos.

Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic   Cooperative Oncology Group study (HeCOG).

Leuk Lymphoma 47(10):2140-2146, 2006.

  1.  

G.Fountzilas, G.Karkavelas, A.Kalogera-Fountzila, M.Karina, M.Ignatiadis, G.Koukoulis, G.Plataniotis, D.Misailidou, M.Bobos, D.Pectasides, E.Razis, A.Karavelis, P.Selviaridis.

Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation.

Anticancer Res 26:4675-4686, 2006.

  1.  

G.Fountzilas, D.Pectasides CH.Christodouloy, E.Timotheadou, TH.Economopoulos, P.Papakostas, CH.Papadimitriou, H.Gogas, I.Efstratiou, D.Skarlos.

Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly docetaxel. Is feasible and safe in high-risk patients with breast cancer.

Med Oncol 23: 479-488, 2006.

  1.  

L.Dova, G.Pentheroudakis, I.Georgiou, V.Malamou-Mitsi, G.Vartholomatos, G.Fountzilas, N.Kolaitis, E.Kitsiou, N.Pavlidis.

Global profiling of EGFR gene mutation, amplification, and regulation and tissue protein expression in unknown primary carcinomas: to target or not to target?

Clin Exp Metastasis 24(2):79-86, 2007.

  1.  

C.Kolotas, N.Tselis, M.Sommerland, S.Roddiger, T.Schnabel, D.Baltas, A.Kalogera-Fountzila, G.Fountzilas, N.Zamboglou.

Reiradiation for recurrent neck metastases of head and neck tumors using CT guided interstitial 192Ir HDR brachytherapy.

Strahlenther Onkol 183:69-75, 2007.

  1.  

G.Pentheroudakis, P.Pappas, V.Golfinopoulos, G.Fountzilas, M.Nikolaidou, VA.Boumba, T.Vougiouklakis, L.Nikiforidis, E.Tzamakou, O.Siarabi, M.Marselos, N.Pavlidis.

Weekday on-weekend off oral capecitabine: A phase I study of a continuous schedule better simulating protracted fluoropyrimidine therapy.

Cancer Chemother Pharmacol 60(5): 733-739, 2007.

  1.  

S.Armaou, I.Konstantopoulou, T.Anagnostopoulos, E.Razis, I.Boukovinas, N.Xenidis, G.Fountzilas, D.Yannoukakos.

Novel genomic rearrangements in the BRCA1 gene detected in greek breast/ovarian cancer patients.

Eur J Cancer 43: 443-453, 2007.

  1.  

D.Pectasides, C.Valavanis, M.Nikolaou, G.Aravantinos, I.Lekka, D.Skarlos, Ch.Kalofonos, G.Fountzilas, V.Kostopoulou, A.Zizi, T.Economopoulos, P.Arapantoni-Datioti.

Molecular markers in extragonadal germ cell tumours: a matched case-control study.

Histopathology 50(3):394-396, 2007.

  1.  

V.Malamou-Mitsi, O.Crikoni, E.Timotheadou, G.Aravantinos, E.Vrettou, N.Agnantis, G.Fountzilas.

Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer.

Anticancer Res 27(2): 1157-1165, 2007.

  1.  

M.Nikolaou, C.Valavanis, G.Aravantinos, G.Fountzilas, N.Tamvakis, I.Lekka, P.Arapantoni-Dadioti, A.Zizi, Th.Economopoulos, D.Pectasides.

Kit expression in male germ cell tumors.

Anticancer Res 27(3B): 1685-1688, 2007.

  1.  

V.Minas, A.Rolaki, SN.Kalantaridou, J.Sidiropoulos, S.Mitrou, G.Petsas, U.Jeschke, EA.Paraskevaidis, G.Fountzilas, GP.Chrousos, N.Pavlidis, A.Makrigiannakis.

Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation.

Brit J Cancer 97(5): 637-645, 2007.

  1.  

D.V.Skarlos, M.Bai, A.Goussia, E.Samantas, E.Galani, D.Tsavdaridis, M.Karina, P.Papakostas, A.Konstantara, G.Fountzilas.

Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group.

Anticancer Res 27(4C): 2973-84, 2007.

  1.  

D.Pectasides, E.Samantas, G.Fountzilas, E.Briasoulis, P.Kosmidis, D.Skarlos, MA.Dimopoulos, HP.Kalofonos, T.Economopoulos, K.Syrigos.

Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group.

Lung Cancer 58:355-361, 2007.

  1.  

T.Makatsoris, P.Papakostas, H.P.Kalofonos, I.Xanthakis, D.Tsavdaridis, G.Aravantinos, H.Gogas, G.Klouvas, P.Kosmidis, D.Pectasides, G.Fountzilas.

Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer: A Hellenic Cooperative Oncology Group (HeCOG) phase II study.

Med Oncol 24(3): 301-307, 2007.

  1.  

N.Tselis, C.Kolotas, G.Birn, S.Roddiger, I.Filipowicz, M.Kontova, G.Fountzilas, P.Selviaridis, D.Baltas, G.Anagnostopoulos, N.Zamboglou.

CT-Guided Interstitial HDR Brachytherapy for Recurrent Glioblastoma Multiforme: Long-Term Results.

Strahlenther Onkol 183(10):563-570, 2007.

  1.  

T. Economopoulos, A. Psyrri, M.A. Dimopoulos, A. Kalogera-Fountzila, N. Pavlidis, C. Tsatalas, C.Nikolaides, S. Mellou, N. Xiros, G. Fountzilas.

CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: results of the HE22A99 trial of the Hellenic Cooperative Oncology Group.

Cancer J 13:327-334, 2007.

  1.  

S.Papadopoulos, G.Kouvatseas, D.Skarlos, N.Malamos, E.Delliou, I.Saratsiotou, A.Ardavanis, D.Mavroudis, E.Skarpidi, P.Arapantoni, I.Karyda, F.Patakioyta, G. Aravantinos, E.Razis, G.Fountzilas, P.Kosmidis.

Comparison of HER2 detection methods between central and regional laboratories in Greece.

Clin Breast Cancer 7: 784-90, 2007.

  1.  

A.Onyenadum, H.Gogas, C.Markopoulos, D.Bafaloukos, G.Aravantinos, M.Mantzourani, A.Koutras, E.Tzorakoelefterakis, N.Xiros, T.Makatsoris, G.Fountzilas, H.P.Kalofonos.

Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer.

J Chemother 19: 582-589, 2007.

  1.  

P.A.Kosmidis, M.A. Dimopoulos, K. Syrigos, C. Nicolaides, G. Aravantinos, I. Boukovinas, D. Pectasides, G. Fountzilas, D. Bafaloukos, C. Bacoyiannis, H.P. Kalofonos.

Gemcitabine versus Gemcitabine-Carboplatin for Patients with Advanced Non-Small Cell Lung Cancer and a Performance Status of 2: A Prospective Randomized Phase II Study of the Hellenic Cooperative Oncology Group.

J Thorac Oncol 2: 135-140, 2007.

  1.  

D. Pectasides, G. Papaxoinis, E. Pectasides, H. Galani, E. Razi, N. Katodrytis, G. Fountzilas, T. Economopoulos.

Merkel cell carcinoma of the skin: A retrospective study of 24 cases by the Hellenic Cooperative Oncology Group (HeCOG).

Oncology 72: 211-218, 2007.

  1.  

E.Timotheadou, D.V.Skarlos, E.Samantas, S.Papadopoulos, S.Murray, J.Skrickova, C.Christodoulou, C.Papakostantinou, D.Pectasides, P.Papakostas, J.Kaplanova, E.Vrettou, M.Karina, P.Kosmidis, G.Fountzilas.

Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients.

Anticancer Res 27: 4481- 4490, 2007.

  1.  

O.Tzaida, H.Gogas, U.Dafni, A.Kyroydi, Ipapaspyrou, V.Kyriakou, V.Malamou-Mitsi, M.Alamani, C.Skopa, I.Kostopoulos, E.Kastritis, D.Pectasides, E.Briasoulis, H.Kalofonos, G.Aravantinos, G.Foutzilas, P.Arapantoni-Dadioti.

Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients patisipating in a randomized study with does-dense sequential adjuvant chemotherapy.

Oncology 72: 388-396, 2007.

  1.  

P. Kosmidis, G. Fountzilas, S. Baka, E. Samantas, AM. Dimopoulos, H. Gogas, D. Skarlos, P. Papacostas, J. Boukovinas, Ch. Bakogiannis, P. Pantelakos, H. Athanasiou, D. Misailidou, P. Tsekeris, N. Pavlidis.

Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A hellenic cooperative oncology group (HeCOG) phase II study.

Anticancer Res 27: 4391-4395, 2007.

  1.  

T. Economopoulos, A. Psyrri, MA. Dimopoulos, A. Kalogera-Fountzila, N. Pavlidis, C. Tsatalas, C. Nikolaides, S. Mellou, N. Xiros, G. Fountzilas.

CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: results of the HE22A99 trial of the Hellenic Cooperative Oncology Group.

Cancer J. 13(5):327-34, 2007.

  1.  

D.Pectasides, G.Fountzilas, G.Aravantinos, A.Bamias, H.P.Kalofonos, D. Skarlos, E. Briasoulis, A. Konstantara, Th. Economopoulos, M.A Dimopoulos.

Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? The Hellenic Cooperative Oncology Group experience.

Inter J Gynaecol Cancer 17:1003-1010, 2007.

  1.  

D.Pestacides, N.Xiros, G.Papaxoinis, E.Pestacides, C.Sykionis, A.Koumarianou, A.Psyri, A.Gaglia, D.Kassanos, P.Gouveris, S.Panayiotidis, G.Fountzilas, T.Economopoulos.

Carboplatin and paclitaxel in advanced or metastatic endometrial cancer.

Gynecol Oncol 109(2):250-254,2008.

  1.  

P.A. Kosmidis, H.P. Kalofonos, C. Christodoulou, K. Syrigos, T. Makatsoris, D. Skarlos, C. Bakogiannis, C. Nicolaides, D. Bafaloukos, A. Bamias, E. Samantas, N. Xiros, I. Boukovinas, G.Fountzilas, M.A. Dimopoulos.

Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.

Ann Oncol 19: 115-122, 2008.

  1.  

I.Konstantopoulou, T.Rampias, A.Ladopoulou, G.Koutsodontis, S.Armaou, T.Anagnostopoulos, G.Nikolopoulos, S.Kamakari, G.Nounesis, A.Stylianakis, C.Karanikiotis, E.Razis, H.Gogas, A.Keramopoulos, V.Gaki, C.Markopoulos, D.Skarlos, N.Pandis, T.Bei, I.Arzimanoglou, G.Fountzilas, D.Yannoukakos.

Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients.

Breast Cancer Res Treat 107:431–441, 2008.

  1.  

E.Briasoulis, G.Fountzilas, A.Bamias, M.A.Dimopoulos, N.Xiros, G.Aravantinos, E.Samantas, H.Kalofonos, T.Makatsoris, N.Mylonakis, P.Papakostas, D.Skarlos, I.Varthalitis, N.Pavlidis.

Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study.

Cancer Chemoth Pharmacol 62: 277-244, 2008.

  1.  

G. Fountzilas, U. Dafni, H.Gogas, H.Linardou, HP.Kalofonos, E.Briasoulis, D.Pectasides, E.Samantas, D.Bafaloukos, GP.Stathopoulos, M.Karina, C.Papadimitriou, D.Skarlos, N.Pisanidis, P.Papakostas, C.Markopoulos, E.Tzorakoeleftherakis, K.Dimitrakakis, P.Makrantonakis, N.Xiros, A.Polichronis, I.Varthalitis, C.Karanikiotis, AM.Dimopoulos.

Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology. Group randomized phase III trial HE 10/00.

Ann Oncol 19: 853-860, 2008.

  1.  

L.Dova, G.Pentheroudakis, V.Golfinopoulos, V.Malamou-Mitsi, I.Georgiou, G.Vartholomatos, A.Ntemou, G.Fountzilas, N.Pavlidis.

Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit.

J Cancer Res Clin Oncol 134(6): 697-704, 2008.

  1.  

G.Papaxoinis, G. Fountzilas, D. Rontogianni, M.A. Dimopoulos, N. Pavlidis, C. Tsatalas, D. Pectasides, N. Xiros, T. Economopoulos.

Low-grade Mucosa-Associated Lymphoid Tissue Lymphoma: A Retrospective Analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG).

Annal Oncol 19(4):780-786, 2008.

  1.  

T.Economopoulos, A. Psyrri, G. Fountzilas, C. Tsatalas, A. Anagnostopoulos, S. Papageorgiou, N. Xiros, M.A. Dimopoulos.

Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: Promising results in marginal zone lymphoma.

Leuk & Lymphoma 49: 68-74, 2008.

  1.  

T.Anagnostopoulos, M.Pertesi, I.Konstantopoulou, S.Armaou, S.Kamakari, G.Nasioulas, A.Athanasiou, A.Dobrovic, M.A.Young, D.Goldgar, G.Fountzilas, D.Yannoukakos.

G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history.

Breast Cancer Res  Treat 110: 377-385, 2008.

  1.  

G.Pentheroudakis, E.Briasoulis, HP.Kalofonos, G.Fountzilas, T. Economopoulos, G.Samelis, A.Koutras, M.Karina, N.Xiros, E.Samantas, A.Bamias, N.Pavlidis.

Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study.

Acta Oncol 47(6):1148-55, 2008.

  1.  

CA. Papadimitriou, D.Bafaloukos, G. Bozas, H. Kalofonos, P. Kosmidis, G. Aravantinos, G. Fountzilas, MA. Dimopoulos.

Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: A Hellenic Co-operative Oncology Group (HeCOG) study.

Gynecol Oncol 110: 87-92, 2008.

  1.  

D.Pectasides, G.Papaxoinis, G.Fountzilas, G.Aravantinos, E.Pectasides, D. Mouratidou, T.Economopoulos, Ch.Andreadis.

Adult granulosa cell tumors of the ovary: a clinicopathological study of 34 patients by the Hellenic Cooperative Oncology Group (HeCOG).

Anticancer Res 28(2B):1421-7, 2008.

  1.  

C.Karanikiotis, M.Daniilidis, N.Karyotis, C.Bakogiannis, T.Economopoulos, S.Murray, D.Papamichael, E.Samantas, A.Nikolaou, L.Skoura, N.Tselis, N.Zamboglou, G.Fountzilas.

HLA Class II alleles and the presence of Circulating Epstein-Barr virus DNA in Greek Patients with nasopharyngeal Carcinoma.

Strahlenther Onkol 184(6):325-331, 2008.

  1.  

C.Papadimitriou, P.Papakostas, E. Timotheadou, G. Aravantinos, A. Bamias and G.Fountzilas.

Adjuvant Dose-Dense sequential Chemotherapy with Epirubicin, CMF and Weekly Paclitaxel in Patients with High-Risk Operable Breast Cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study.

Cancer Invest 26(5):491-8, 2008.

  1.  

V.Siafaka, TN.Hyphantis, I.Alamanos, G.Fountzilas, D.Skarlos, D. Pectasides, V.Mavreas, N.Pavlidis.

Personality factors associated with psychological distress in testicular cancer survivors.

J Pers Assess 90(4):348-55, 2008.

  1.  

G.Lazaridis, G.Pentheroudakis, G.Fountzilas, N.Pavlidis.

Liver metastases from cancer of unknown primary (CUPL): A retrospective analysis of presentation, management and prognosis in 49 patients and systematic review of the literature.

Cancer Treat Rev 34(8): 693-700, 2008.

  1.  

IJ.Dahabreh, H.Linardou, F.Siannis, G.Fountzilas, S.Murray.

Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Oncologist 13(6):620-30, 2008.

  1.  

HP.Kalofonos, A.Bamias, A.Koutras, P.Papakostas, G.Basdanis, E.Samantas, M.Karina, D.Misailidou, N.Pisanidis, G.Pentheroudakis, T.Economopoulos, C.Papadimitriou, DV.Skarlos, D.Pectasides, M. Stavropoulos, D.Bafaloukos, D.Kardamakis, C.Karanikiotis, G.Vourli, G.Fountzilas.

A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: A Hellenic Cooperative Oncology Group Study.

Eur J Cancer 44(12):1693-700, 2008.

  1.  

CA.Papadimitriou, G.Fountzilas, D.Bafaloukos, G.Bozas, H.Kalofonos, D.Pectasides, G.Aravantinos, A.Bamias, MA.Dimopoulos.

Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: A Hellenic Co-operative Oncology Group (HeCOG) study.

Gynecol Oncol 111(1):27-34, 2008

  1.  

G.Aravantinos, G.Fountzilas, A.Bamias, I.Grimani, S.Rizos, HP.Kalofonos, DV.Skarlos, T.Economopoulos, PA.Kosmidis, GP.Stathopoulos, E. Briasoulis, D.Pectasides, E.Samantas, E.Timotheadou, C.Papadimitriou, A. Papanikolaou, A.Onyenadum, P.Papakostas, D.Bafaloukos, MA.Dimopoulos. Carboplatin and Paclitaxel versus Cisplatin,

Paclitaxel and Doxorubicin for first-line chemotherapy of advanced ovarian cancer: A Hellenic Cooperative Oncology Group (HeCOG) study.

Eur J Cancer 44(15):2169-77, 2008.

  1.  

E.Razis, E.Briasoulis, E.Vrettou, DV.Skarlos, D.Papamichael, I.Kostopoulos, E.Samantas, I.Xanthakis, M.Bobos, E.Galanidi, M.Bai, I. Gikonti, A.Koukouma, G.Kafiri, P.Papakostas, KT.Kalogeras, P.Kosmidis, G.Fountzilas.

Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study.

BMC Cancer 8(1):234, 2008.

  1.  

D.Mauri, D.Tzachanis, P.Tsekoura, I.Xanthakis, L.Tsali, S.Roumbkou, G.Fountzilas.

Weekly docetaxel regimens and radiation pneumonitis.

J Support Oncol 6(6):265-6, 2008.

  1.  

G.Fountzilas, M.Bobos, A.Kalogera-Fountzila, N.Xiros, S.Murray, H.Linardou, G.Karayannopoulou, A.Koutras, D.Bafaloukos, E.Samantas, Ch.Christodoulou, T. Economopoulos, K.T. Kalogeras, P.Kosmidis.

Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer. A phase II study of the Hellenic Cooperative Oncology Group with biomarker evaluation.

Cancer Invest 26(8):784-93, 2008.

  1.  

AK.Koutras, KT.Kalogeras, MA.Dimopoulos, RM.Wirtz, U.Dafni, E. Briasoulis, D.Pectasides, H.Gogas, C.Christodoulou, G.Aravantinos, G. Zografos, E.Timotheadou, P.Papakostas, H.Linardou, E.Razis, T.Economopoulos, HP.Kalofonos, G.Fountzilas.

Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study.

Br J Cancer 99:1775-1785, 2008.

  1.  

G.Pentheroudakis, G.Fountzilas, H.P.Kalofonos,V.Golfinopoulos, G. Aravantinos, D. Bafaloukos, P. Papakostas, D. Pectasides, C. Christodoulou, K. Syrigos, T. Economopoulos, N. Pavlidis; Hellenic Cooperative Oncology Group.

Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.

Crit Rev Oncol Hematol 66(3):237-47, 2008.

  1.  

AK.Koutras, G.Fountzilas, U.Dafni, MA.Dimopoulos, D.Pectasides, G.Klouvas, P.Papakostas, P.Kosmidis, E.Samantas, H.Gogas, E.Briasoulis, G.Vourli, T.Petsas, N.Xiros, HP.Kalofonos.

Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology Group.

Anticancer Res 28(5B):2913-20, 2008.

  1.  

A.Bamias, G.Fountzilas, M. Michael, C. Konstantaras, E. Vrettou, E. Eleftheriadis, P. Papakostas, K. Papadimitriou, N. Pavlidis, N. Xiros, M. Bai.

DCC and TS protein expression in resected gastric cancer: A Hellenic Cooperative   Oncology Group study.

Cent Eur J Med 3:29-39, 2008.

  1.  

N.Maniadakis, U.Dafni, V.Fragoulakis, I.Grimani, E.Galani, A.Fragkoulidi, G.Fountzilas.

Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial.

Ann Oncol 20:278-285, 2009.

  1.  

D.Pectasides, U.Dafni, D.Bafaloukos, D.Skarlos, A.Polyzos, D.Tsoutsos, H. Kalofonos, G.Fountzilas, P.Panagiotou, G.Kokkalis, O.Papadopoulos, O. Castana, S.Papadopoulos, E.Stavrinidis, G.Vourli, J.Ioannovich, H.Gogas.

Randomized phase III study of one month versus one year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma.

J Clin Oncol. 27(6):939-44, 2009.

  1.  

G.Fountzilas, U.Dafni, MA.Dimopoulos, A.Koutras, D.Skarlos, P.Papakostas, H. Gogas, D. Bafaloukos, A.Kalogera-Fountzila, E.Samantas, E.Briasoulis, D.Pectasides, N.Maniadakis, F.Matsiakou, G.Aravantinos, C.Papadimitriou, M. Karina, C. Christodoulou, P. Kosmidis, HP. Kalofonos.

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: A Hellenic Cooperative Oncology Group study.

Br Can Res Treat 115(1):87-99, 2009.

  1.  

G.Fountzilas, A.Bamias, A.Kalogera-Fountzila, G.Karayannopoulou, M. Bobos, E.Athanassiou, KT.Kalogeras, C.Tolis, P.Tsekeris, P.Papakostas, C. Vamvouka, T.Zaramboukas, P.Kosmidis, N.Zamboglou, D.Misailidou.

Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck.

Anticancer Res 29(2):529-538, 2009.

  1.  

C.Christodoulou, I.Kostopoulos, HP.Kalofonos, E.Lianos, M.Bobos, E. Briasoulis, H.Gogas, E.Razis, DV.Skarlos, G.Fountzilas.

Study of the Hellenic  Cooperative Oncology Group. Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. A Phase II Study of the Hellenic   Cooperative Oncology Group (HeCOG) with biomarker evaluation.

Oncology 76(4):275-85, 2009.

  1.  

G.Pentheroudakis, KT. Kalogeras, RM. Wirtz, I.Grimani, G.Zografos, H. Gogas, U.Stropp, D.Pectasides, D.Skarlos, G.Hennig, E.Samantas, D. Bafaloukos, P.Papakostas, HP.Kalofonos, N.Pavlidis, G.Fountzilas.

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Breast Cancer Res Treat116: 131-143, 2009.

  1.  

C.Christodoulou, U.Dafni, G.Aravantinos, A.Koutras, E.Samantas, M. Karina, J.Janinis, P.Papakostas, D.Skarlos, HP.Kalofonos, G.Fountzilas.

Effects of epoetin-alpha on quality of life of cancer patients with solid tumors receiving chemotherapy.

Anticancer Res. 29(2):693-702, 2009.

  1.  

D.Pectasides, G.Papaxoinis, M.Nikolaou, C.Valavanis, G.Aravantinos, G.Fountzilas, N.Tamvakis, E.Pectasides, I.Lekka, P.Arapantoni-Dadioti, A. Zizi, I.Ghiconti, T.Economopoulos.

Analysis of 7 immunohistochemical markers in male germ cell tumors demonstrates the prognostic significance of P53 and MIB-1.

Anticancer Res 29(2): 737-44, 2009.

  1.  

D.Pectasides, G.Papaxoinis, G.Fountzilas, G.Aravantinos, A.Bamias, N.Pavlidis, HP.Kalofonos, E.Timotheadou, E.Samantas, E.Briasoulis, DV. Skarlos, T.Economopoulos, MA.Dimopoulos.

Epithelial ovarian cancer in Greece: a retrospective study of 1791 patients by the Hellenic Cooperative Oncology Group (HeCOG).

Anticancer Res 29(2): 745-52, 2009.

  1.  

S.Armaou, M.Pertesi, F.Fostira, G.Thodi, PS.Athanasopoulos, S.Kamakari, A.Athanasiou, H.Gogas, D.Yannoukakos, G.Fountzilas, I.Konstantopoulou.

Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases.

Br J Can 101(1): 32-7, 2009.

  1.  

D.Pectasides, G.Fountzilas, G.Papaxoinis, E.Pectasides, N.Xiros, C. Sykiotis, A.Koumarianou, A.Psyrri, J.Panayiotides, T.Economopoulos.

Carboplatin and paclitaxel in metastatic or recurrent cervical cancer.

Int J Gynecol Cancer 19(4): 777-81, 2009.

  1.  

D.Pectasides, E.Pectasides, G.Papaxoinis, C.Andreadis, G.Papatsibas, G. Fountzilas., K.Pliarchopoulou, A.Macheras, G.Aravantinos, T. Economopoulos.

Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients.

Gynecol Oncol 115(1): 97-101, 2009.

  1.  

DV.Skarlos, E.Timotheadou, E.Galani, E.Samantas, I.Grimani, E.Lianos, G. Aravantinos, I.Xanthakis, G.Pentheroudakis, D.Pectasides, G.Fountzilas.

Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.

Oncology 77(2): 107-12, 2009.

  1.  

G.Lainakis, A.Bamias, E.Psimenou, G.Fountzilas, MA.Dimopoulos.

Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the Hellenic Cooperative Oncology Group.

Clin Nephrol 72(1): 73-78, 2009.

  1.  

B.Escudier, J.Roigas, S.Gillessen, U.Harmenberg, S.Srinivas, SF.Mulder, G. Fountzilas, C.Peschel, P.Flodgren, EC.Maneval, I.Chen, NJ.Vogelzang.

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.

J Clin Oncol 27(25): 4068-75, 2009.

  1.  

CA.Papadimitriou, H.Kalofonos, F.Zagouri, P.Papakostas, G.Bozas, T. Makatsoris, MA.Dimopoulos, G.Fountzilas.

Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group.

Oncology 77 (3-4): 212-6, 2009.

  1.  

I.Kostopoulos, V.Karavasilis, M.Karina, M.Bobos, N.Xiros, G. Pentheroudakis, G.Kafiri, P.Papakostas, E.Vrettou, G.Fountzilas.

Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.

BMC Cancer 9: 339, 2009.

  1.  

E.Razis, P.Selviaridis, S.Labropoulos, JL.Norris, MJ.Zhu, DD.Song, T. Kalebic, M.Torrens, A.Kalogera-Fountzila, G.Karkavelas, S.Karanastasi, JA. Fletcher, G.Fountzilas.

Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.

Clin Cancer Res 15(19): 6258-66, 2009.

  1.  

E.Briasoulis, P.Pappas, C.Puozzo, C.Tolis, G.Fountzilas, U.Dafni, M. Marselos, N.Pavlidis.

Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer.

Clin Cancer Res 15(20): 6454-61, 2009.

  1.  

G.Pentheroudakis, N.Angouridakis, R.Wirtz, A.Nikolaou, KT.Kalogeras, N. Pavlidis, G.Fountzilas.

Transcriptional activity of human epidermal growth factor receptor family and angiogenesis effectors in locoregionally recurrent head and neck squamous cell carcinoma and correlation with patient outcome.

J Oncol 2009: 854127, 2009.

  1.  

V.Kotoula, E.Charalambous, B.Biesmans, A.Malousi, E.Vrettou, G.Fountzilas, G.Karkavelas

Targeted KRAS Mutation Assessment on Patient Tumor Histologic Material in Real Time Diagnostics.

PLoS ONE 4(11):7746, 2009.

  1.  

G.Mountzios, MA.Dimopoulos, A.Bamias, G.Vourli, H.Kalofonos, G. Aravantinos, G.Fountzilas, CA.Papadimitriou.

Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic   Cooperative Oncology Group (HeCOG) study.

Ann Oncol 20(8):1362-1368, 2009.

  1.  

N.Maniadakis, V.Fragoulakis, D.Pectasides, G.Fountzilas.

XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis.

Curr Med Res Opin 25(3):797-805, 2009.

  1.  

A.Koumarianou, G.Fountzilas, P.Kosmidis, G.Klouvas, E.Samantas, C. Kalofonos, G.Pentheroudakis, T.Economopoulos, D.Pectasides.

Non small cell lung cancer in the elderly: clinico-pathologic, management and outcome characteristics in comparison to younger patients.

J Chemother. 21(5):573-83, 2009.

  1.  

G.Fountzilas, A.Kalogera-Fountzila,S.Lambaki, R.M. Wirtz, A. Nikolaou, G. Karayannopoulou, M. Bobos, V. Kotoula, S. Murray, A. Lambropoulos, G. Aravantinos, K. Markou, E. Athanassiou, D. Misailidou, K.T. Kalogeras, D. Skarlos.

MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer.

J Oncol 2009:30590, 2009.

  1.  

G.Iliadis, P.Selviaridis, A.Kalogera-Fountzila, A.Fragkoulidi, D.Baltas, N. Tselis, A.Chatzisotiriou, D.Misailidou, N.Zamboglou, G.Fountzilas.

The importance of tumor volume in the prognosis of patients with glioblastoma: comparison of computerized volumetry and geometric models.

Strahlenther Onkol. 185(11):743-50, 2009.

  1.  

G.Pentheroudakis, L.Kostadima, L.Dova, I.Georgiou, T.Tzavaras, G.Vartholomatos, RM.Wirtz, G.Fountzilas, V.Malamou-Mitsi, N.Pavlidis.

A twisted kiss: in vitro and in vivo evidence of genetic variation and suppressed transcription of the metastasis-suppressor gene KiSS1 in early breast cancer.

Neoplasma 57(1):47-54, 2010.

  1.  

G.Fountzilas, A.Fragkoulidi, A.Kalogera-Fountzila, M.Nikolaidou, M. Bobos, J.Calderaro, F.Andreiuolo, M.Marselos.

A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer.

Cancer Chemother Pharmacol 65(4):694-60, 2010.

  1.  

D. Bafaloukos, H. Linardou, G. Aravantinos, C. Papadimitriou, A. Bamias, G. Fountzilas, HP. Kalofonos, P. Kosmidis, E. Timotheadou, T. Makatsoris, E. Samantas, E. Briasoulis, C. Christodoulou, P. Papakostas, D. Pectasides, AM. Dimopoulos.

A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.

BMC Med 8(1):3, 2010.

  1.  

N. Katirtzoglou, I. Gkiozos, N. Makrilia, E. Tsaroucha, A. Rapti, G. Stratakos, G. Fountzilas, KN. Syrigos.

Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.

Clin Lung Cancer 11(1):30-5, 2010.

  1.  

U.Dafni, I.Grimani, A.Xyrafas, AG.Eleftheraki, G.Fountzilas.

Fifteen-year trends in metastatic breast cancer survival in Greece.

Breast Cancer Res Treat 119(3):621-31, 2010.

  1.  

A.Bamias, A. Karadimou, S.Lampaki, K. Papazisis, G. Lainakis, L.Malettou, E. Timotheadou, K.Papazisis, C. Andraeadis, L. Kontovinis, I. Anastasiou, K.Stravodimos, I. Xanthakis, A. Skolarikos, C.Christodoulou, K. Syrigos, C. Papandreou, Razi E, U.Dafni, G.Fountzilas, M.A.Dimopoulos.

Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model.

BMC Cancer 10(1):45, 2010.

  1.  

A.Bamias, M.Karina, P.Papakostas, I.Kostopoulos, M.Bobos, G.Vourli, E.Samantas, Ch.Christodoulou, G.Pentheroudakis, D.Pectasides, M.A. Dimopoulos, G.Fountzilas.

A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer.

Cancer Chemo Pharmacol (65)6:1009-1021, 2010.

  1.  

AK.Koutras, G.Fountzilas, T.Makatsoris, S.Peroukides, HP.Kalofonos.

Bevacizumab in the treatment of breast cancer.

Cancer Treat Rev 36(1):75-82, 2010.

  1.  

H. Gogas, G. Pentheroudakis, A. Antoniadis, S. Murray, G. Fountzilas

The role of taxanes in the management of patients with early breast cancer: a review of the clinical evidence and molecular mechanisms of resistance.

Cancer and Chemotherapy Rev 3, 2008. Ahead of print.

  1.  

AK.Koutras, G.Fountzilas, KT.Kalogeras, I.Starakis, G.Iconomou, HP. Kalofonos.

The upgraded role of HER3 and HER4 receptors in breast cancer.

Crit Rev Oncol Hematol 74: 73-78, 2010.

  1.  

H.Gogas, D.Pectasides, I.Kostopoulos, E. Lianos, D.Skarlos, G.Papaxoinis, M.Bobos, H.P.Kalofonos, K.Petraki, K.Pavlakis, D.Bafaloukos, G.Fountzilas.

Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: a phase II trial of the Hellenic Cooperative Oncology Group.

Clin Breast Cancer. 2010 Jun;10(3):230-7.

  1.  

E.Pectasides, AM.Egloff, C.Sasaki, P.Kountourakis, B.Burtness, G. Fountzilas, U.Dafni, T.Zaramboukas, T.Rampias, D.Rimm, J.Grandis, A. Psyrri.

Nuclear Localization of Signal Transducer and Activator of Transcription 3 in Head and Neck Squamous Cell Carcinoma Is Associated with a Better Prognosis.

Clin Cancer Res. 2010 Apr 15;16(8):2427-34

  1.  

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Lancet Oncol. 2010 Aug; 11(8):753-62.

  1.  

Briasoulis E, Golfinopoulos V, Karina M, Papakostas P, Pavlidis N, Fountzilas G.

Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.

Anticancer Drugs. 2010 Sep;21(8):785-9.

  1.  

Fostira F, Thodi G, Sandaltzopoulos R, Fountzilas G, Yannoukakos D.

Mutational spectrum of APC and genotype-phenotype correlations in Greek FAP patients.

BMC Cancer. 2010 Jul 22;10: 389.

  1.  

Ihnen M, Wirtz RM, Kalogeras KT, Milde-Langosch K, Schmidt M, Witzel I, Eleftheraki AG, Papadimitriou C, Jänicke F, Briassoulis E, Pectasides D, Rody A, Fountzilas G, Müller V.

Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer.

Br J Cancer. 2010 Sep 28;103 (7):1048-56.

  1.  

Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, Healey S, Morrison J, Kartsonaki C, Lesnick T, Ghoussaini M, Barrowdale D; EMBRACE, Peock S, Cook M, Oliver C, Frost D, Eccles D, Evans DG, Eeles R, Izatt L, Chu C, Douglas F, Paterson J, Stoppa-Lyonnet D, Houdayer C, Mazoyer S, Giraud S, Lasset C, Remenieras A, Caron O, Hardouin A, Berthet P; GEMO Study Collaborators, Hogervorst FB, Rookus MA, Jager A, van den Ouweland A, Hoogerbrugge N, van der Luijt RB, Meijers-Heijboer H, Gómez García EB; HEBON, Devilee P, Vreeswijk MP, Lubinski J, Jakubowska A, Gronwald J, Huzarski T, Byrski T, Górski B, Cybulski C, Spurdle AB, Holland H; kConFab, Goldgar DE, John EM, Hopper JL, Southey M, Buys SS, Daly MB, Terry MB, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Preisler-Adams S, Arnold N, Niederacher D, Sutter C, Domchek SM, Nathanson KL, Rebbeck T, Blum JL, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Blank SV, Friedman E, Kaufman B, Laitman Y, Milgrom R, Andrulis IL, Glendon G, Ozcelik H, Kirchhoff T, Vijai J, Gaudet MM, Altshuler D, Guiducci C; SWE-BRCA, Loman N, Harbst K, Rantala J, Ehrencrona H, Gerdes AM, Thomassen M, Sunde L, Peterlongo P, Manoukian S, Bonanni B, Viel A, Radice P, Caldes T, de la Hoya M, Singer CF, Fink-Retter A, Greene MH, Mai PL, Loud JT, Guidugli L, Lindor NM, Hansen TV, Nielsen FC, Blanco I, Lazaro C, Garber J, Ramus SJ, Gayther SA, Phelan C, Narod S, Szabo CI; MOD SQUAD, Benitez J, Osorio A, Nevanlinna H, Heikkinen T, Caligo MA, Beattie MS, Hamann U, Godwin AK, Montagna M, Casella C, Neuhausen SL, Karlan BY, Tung N, Toland AE, Weitzel J, Olopade O, Simard J, Soucy P, Rubinstein WS, Arason A, Rennert G, Martin NG, Montgomery GW, Chang-Claude J, Flesch-Janys D, Brauch H; GENICA, Severi G, Baglietto L, Cox A, Cross SS, Miron P, Gerty SM, Tapper W, Yannoukakos D, Fountzilas G, Fasching PA, Beckmann MW, Dos Santos Silva I, Peto J, Lambrechts D, Paridaens R, Rüdiger T, Försti A, Winqvist R, Pylkäs K, Diasio RB, Lee AM, Eckel-Passow J, Vachon C, Blows F, Driver K, Dunning A, Pharoah PP, Offit K, Pankratz VS, Hakonarson H, Chenevix-Trench G, Easton DF, Couch FJ.

A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population.

Nat Genet. 2010 Oct;42(10):885-92.

  1.  

Kosmidis PA, Fountzilas G, Eleftheraki AG, Kalofonos HP, Pentheroudakis G, Skarlos D, Dimopoulos MA, Bafaloukos D, Pectasides D, Samantas E, Boukovinas J, Lambaki S, Katirtzoglou N, Bakogiannis C, Syrigos KN.

Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG).

Ann Oncol. 2010 Sep 29.

  1.  

Thodi G, Fostira F, Sandaltzopoulos R, Nasioulas G, Grivas A, Boukovinas I, Mylonaki M, Panopoulos C, Brankovic Magic M, Fountzilas G, Yannoukakos D. Screening of the DNA mismatch repair genes MLH1, MSH2 and MSH6 in a Greek cohort of Lynch syndrome suspected families.

BMC Cancer. 2010 Oct 11;10(1):544.

  1.  

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S.

Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.

J Natl Cancer Inst Monogr. 2010 (41):162-77. Review.

  1.  

Kalofonos HP, Papakostas P, Makatsoris T, Papamichael D, Vourli G, Xanthakis I, Aravantinos G, Papadimitriou C, Pentheroudakis G, Varthalitis I, Samelis G, Syrigos KN, Xiros N, Stavropoulos M, Kosmidis P, Christodoulou C, Linardou H, Skondra M, Pectasides D, Economopoulos T, Fountzilas G.

Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.

Anticancer Res. 2010 Oct;30(10):4325-33.

  1.  

Gogas H, Dafni U, Koon H, Spyropoulou-Vlachou M, Metaxas Y, Buchbinder E, Pectasides E, Tsoutsos D, Polyzos A, Stratigos A, Markopoulos C, Panagiotou P, Fountzilas G, Castana O, Skarlos P, Atkins MB, Kirkwood JM.

Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial.

J Transl Med. 2010 Nov 3;8:108.

  1.  

Tselis N, Ratka M, Vogt HG, Kolotas C, Baghi M, Baltas D, Fountzilas G, Georgoulias V, Ackermann H, Zamboglou N.

Hypofractionated accelerated CT-guided interstitial ¹⁹²Ir-HDR-Brachytherapy as re-irradiation in inoperable recurrent cervical lymphadenopathy from head and neck cancer.

Radiother Oncol. 2011 Jan;98(1):57-62. Epub 2010 Dec 2.

  1.  

Murray S, Bobos M, Angouridakis N, Nikolaou A, Linardou H, Razis E, Fountzilas G.

Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study.

J Oncol. 2010;2010:709678. Epub 2011 Jan 3.

  1.  

Papadimitriou CA, Papakostas P, Karina M, Malettou L, Dimopoulos MA, Pentheroudakis G, Samantas E, Bamias A, Miliaras D, Basdanis G, Xiros N, Klouvas G, Bafaloukos D, Kafiri G, Papaspirou I, Pectasides D, Karanikiotis C, Economopoulos T, Efstratiou I, Korantzis I, Pisanidis N, Makatsoris T, Matsiakou F, Aravantinos G, Kalofonos HP, Fountzilas G.

A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.

BMC Med. 2011 Jan 31;9:10.

  1.  

Kotoula V, Lambaki S, Televantou D, Kalogera-Fountzila A, Nikolaou A, Markou K, Misailidou D, Syrigos KN, Fountzilas G. STAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN. Transl Oncol. 2011 Feb 1;4(1):47-58.

  1.  

Pectasides E, Rampias T, Kountourakis P, Sasaki C, Kowalski D, Fountzilas G, Zaramboukas T, Rimm D, Burtness B, Psyrri A.

Comparative prognostic value of epidermal growth factor quantitative protein expression compared with FISH for head and neck squamous cell carcinoma.

Clin Cancer Res. 2011 May 1;17(9):2947-54. Epub 2011 Feb 25.

  1.  

Pentheroudakis G, Batistatou A, Kalogeras KT, Kronenwett R, Wirtz RM, Bournakis E, Eleftheraki AG, Pectasides D, Bobos M, Papaspirou I, Kamina S, Gogas H, Koutras AK, Pavlidis N, Fountzilas G.

Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study.

Breast Cancer Res Treat. 2011 May;127(1):179-93. Epub 2011 Mar 9.

  1.  

Fountzilas G, Ciuleanu E, Bobos M, Kalogera-Fountzila A, Eleftheraki AG, Karayannopoulou G, Zaramboukas T, Nikolaou A, Markou K, Resiga L, Dionysopoulos D, Samantas E, Athanassiou H, Misailidou D, Skarlos D, Ciuleanu T.

Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.

Ann Oncol. 2011 Apr 27. [Epub ahead of print]

  1.  

Razis E, Bobos M, Kotoula V, Eleftheraki AG, Kalofonos HP, Pavlakis K, Papakostas P, Aravantinos G, Rigakos G, Efstratiou I, Petraki K, Bafaloukos D, Kostopoulos I, Pectasides D, Kalogeras KT, Skarlos D, Fountzilas G.

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.

Breast Cancer Res Treat. 2011 Jul;128(2):447-56. Epub 2011 May 19.

  1.  

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R.

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

Lancet. 2011 Aug 27;378(9793):771-84. Epub 2011 Jul 28.

  1.  

Stevens KN, Vachon CM, Lee AM, Slager S, Lesnick T, Olswold C, Fasching PA, Miron P, Eccles D, Carpenter JE, Godwin AK, Ambrosone C, Winqvist R, Brauch H; GENICA consortium, Schmidt MK, Cox A, Cross SS, Sawyer E, Hartmann A, Beckmann MW, Schulz-Wendtland R, Ekici AB, Tapper WJ, Gerty SM, Durcan L, Graham N, Hein R, Nickels S, Flesch-Janys D, Heinz J, Sinn HP, Konstantopoulou I, Fostira F, Pectasides D, Dimopoulos AM, Fountzilas G, Clarke CL, Balleine R, Olson JE, Fredericksen Z, Diasio RB, Pathak H, Ross E, Weaver J, Rüdiger T, Försti A, Dünnebier T, Ademuyiwa F, Kulkarni S, Pylkäs K, Jukkola-Vuorinen A, Ko YD, Van Limbergen E, Janssen H, Peto J, Fletcher O, Giles GG, Baglietto L, Verhoef S, Tomlinson I, Kosma VM, Beesley J, Greco D, Blomqvist C, Irwanto A, Liu J, Blows FM, Dawson SJ, Margolin S, Mannermaa A, Martin NG, Montgomery GW, Lambrechts D, dos Santos Silva I, Severi G, Hamann U, Pharoah P, Easton DF, Chang-Claude J, Yannoukakos D, Nevanlinna H, Wang X, Couch FJ.

Common breast cancer susceptibility loci are associated with triple-negative breast cancer.

Cancer Res. 2011 Oct 1;71(19):6240-9. Epub 2011 Aug 15.

  1.  

Koutras AK, Antonacopoulou AG, Eleftheraki AG, Dimitrakopoulos FI, Koumarianou A, Varthalitis I, Fostira F, Sgouros J, Briasoulis E, Bournakis E, Bafaloukos D, Bompolaki I, Galani E, Kalogeras KT, Pectasides D, Fountzilas G, Kalofonos HP.

Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.

Pharmacogenomics J. 2011 Aug 16. doi: 10.1038/tpj.2011.37. [Epub ahead of print]

  1.  

Fountzilas G, Kourea HP, Bobos M, Televantou D, Kotoula V, Papadimitriou C, Papazisis KT, Timotheadou E, Efstratiou I, Koutras A, Pentheroudakis G, Christodoulou C, Aravantinos G, Miliaras D, Petraki K, Papandreou CN, Papakostas P, Bafaloukos D, Repana D, Razis E, Pectasides D, Dimopoulos AM.

Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the hellenic cooperative oncology group experience with biological marker evaluation.

Anticancer Res. 2011 Sep;31(9):3007-18.

  1.  

Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilas G.

Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.

Cancer Chemother Pharmacol. 2011 Sep 8. [Epub ahead of print]

  1.  

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R.

Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.

Lancet. 2011 Nov 12;378(9804):1707-16. Epub 2011 Oct 19.

  1.  

Pectasides D, Papaxoinis G, Kotoula V, Fountzilas H, Korantzis I, Koutras A, Dimopoulos AM, Papakostas P, Aravantinos G, Varthalitis I, Kosmidis P, Skarlos D, Bournakis E, Bafaloukos D, Kalofonos HP, Kalogeras KT, Fountzilas G.

Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: A Hellenic Cooperative Oncology Group (HeCOG) study.

Oncol Rep. 2012 Jan;27(1):216-24. doi: 10.3892/or.2011.1504. Epub 2011 Oct 13.

  1.  

Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A, Millikan RC, Wang X, Ademuyiwa F, Ahmed S, Ambrosone CB, Baglietto L, Balleine R, Bandera EV, Beckmann MW, Berg CD, Bernstein L, Blomqvist C, Blot WJ, Brauch H, Buring JE, Carey LA, Carpenter JE, Chang-Claude J, Chanock SJ, Chasman DI, Clarke CL, Cox A, Cross SS, Deming SL, Diasio RB, Dimopoulos AM, Driver WR, Dünnebier T, Durcan L, Eccles D, Edlund CK, Ekici AB, Fasching PA, Feigelson HS, Flesch-Janys D, Fostira F, Försti A, Fountzilas G, Gerty SM; The Gene Environment Interaction and Breast Cancer in Germany (GENICA) Consortium, Giles GG, Godwin AK, Goodfellow P, Graham N, Greco D, Hamann U, Hankinson SE, Hartmann A, Hein R, Heinz J, Holbrook A, Hoover RN, Hu JJ, Hunter DJ, Ingles SA, Irwanto A, Ivanovich J, John EM, Johnson N, Jukkola-Vuorinen A, Kaaks R, Ko YD, Kolonel LN, Konstantopoulou I, Kosma VM, Kulkarni S, Lambrechts D, Lee AM, Marchand LL, Lesnick T, Liu J, Lindstrom S, Mannermaa A, Margolin S, Martin NG, Miron P, Montgomery GW, Nevanlinna H, Nickels S, Nyante S, Olswold C, Palmer J, Pathak H, Pectasides D, Perou CM, Peto J, Pharoah PD, Pooler LC, Press MF, Pylkäs K, Rebbeck TR, Rodriguez-Gil JL, Rosenberg L, Ross E, Rüdiger T, Silva ID, Sawyer E, Schmidt MK, Schulz-Wendtland R, Schumacher F, Severi G, Sheng X, Signorello LB, Sinn HP, Stevens KN, Southey MC, Tapper WJ, Tomlinson I, Hogervorst FB, Wauters E, Weaver J, Wildiers H, Winqvist R, Berg DV, Wan P, Xia LY, Yannoukakos D, Zheng W, Ziegler RG, Siddiq A, Slager SL, Stram DO, Easton D, Kraft P, Henderson BE, Couch FJ.

A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer.

Nat Genet. 2011 Oct 30;43(12):1210-1214. doi: 10.1038/ng.985.

  1.  

Psyrri A, Kalogeras KT, Kronenwett R, Wirtz RM, Batistatou A, Bournakis E, Timotheadou E, Gogas H, Aravantinos G, Christodoulou C, Makatsoris T, Linardou H, Pectasides D, Pavlidis N, Economopoulos T, Fountzilas G.

Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study.

Ann Oncol. 2011 Nov 22. [Epub ahead of print]

  1.  

Fountzilas G, Valavanis C, Kotoula V, Eleftheraki AG, Kalogeras KT, Tzaida O, Batistatou A, Kronenwett R, Wirtz RM, Bobos M, Timotheadou E, Soupos N, Pentheroudakis G, Gogas H, Vlachodimitropoulos D, Polychronidou G, Aravantinos G, Koutras A, Christodoulou C, Pectasides D, Arapantoni P.

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.

J Transl Med. 2012 Jan 12;10:10.

  1.  

Iliadis G, Kotoula V, Chatzisotiriou A, Televantou D, Eleftheraki AG, Lambaki S, Misailidou D, Selviaridis P, Fountzilas G.

Volumetric and MGMT parameters in glioblastoma patients: survival analysis.

BMC Cancer. 2012 Jan 3;12:3. doi: 10.1186/1471-2407-12-3.

  1.  

Fountzilas E, Markou K, Vlachtsis K, Nikolaou A, Arapantoni-Dadioti P, Ntoula E, Tassopoulos G, Bobos M, Konstantinopoulos P, Fountzilas G, Spentzos D.

Identification and validation of gene expression models that predict clinical outcome in patients with early-stage laryngeal cancer.

Ann Oncol. 2012 Jan 4. [Epub ahead of print]

  1.  

Fountzilas G, Valavanis C, Kotoula V, Eleftheraki AG, Kalogeras KT, Tzaida O, Batistatou A, Kronenwett R, Wirtz RM, Bobos M, Timotheadou E, Soupos N, Pentheroudakis G, Gogas H, Vlachodimitropoulos D, Polychronidou G, Aravantinos G, Koutras A, Christodoulou C, Pectasides D, Arapantoni P.

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.

J Transl Med. 2012 Jan 12;10(1):10.

  1.  

Stevens KN, Fredericksen Z, Vachon CM, Wang X, Margolin S, Lindblom A, Nevanlinna H, Greco D, Aittomäki K, Blomqvist C, Chang-Claude J, Vrieling A, Flesch-Janys D, Sinn HP, Wang-Gohrke S, Nickels S, Brauch H, Ko YD, Fischer HP, Network TG, Schmutzler RK, Meindl A, Bartram CR, Schott S, Engel C, Godwin AK, Weaver J, Pathak HB, Sharma P, Brenner H, Muller H, Arndt V, Stegmaier C, Miron P, Yannoukakos D, Stavropoulou A, Fountzilas G, Gogas HJ, Swann R, Dwek M, Perkins KA, Milne RL, Benítez J, Zamora MP, Ignacio Arias Pérez J, Bojesen SE, Nielsen SF, Nordestgaard BG, Flyger H, Guénel P, Truong T, Menegaux F, Cordina-Duverger E, Burwinkel B, Marmé F, Schneeweiss A, Sohn C, Sawyer E, Tomlinson I, Kerin MJ, Peto J, Johnson N, Fletcher O, Dos Santos Silva I, Fasching PA, Beckmann MW, Hartmann A, Ekici AB, Lophatananon A, Muir K, Puttawibul P, Wiangnon S, Schmidt MK, Broeks A, Braaf LM, Rosenberg EH, Hopper JL, Apicella C, Park DJ, Southey MC, Swerdlow AJ, Ashworth A, Orr N, Schoemaker MJ, Anton-Culver H, Ziogas A, Bernstein L, Clarke Dur C, Shen CY, Yu JC, Hsu HM, Hsiung CN, Hamann U, Dünnebier T, Rüdiger T, Ulrich Ulmer H, Pharoah PD, Dunning AM, Humphreys MK, Wang Q, Cox A, Cross SS, Reed MW, Hall P, Czene K, Ambrosone CB, Ademuyiwa F, Hwang H, Eccles DM, Garcia-Closas M, Figueroa JD, Sherman ME, Lissowska J, Devilee P, Seynaeve C, Tollenaar RA, Hooning MJ, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, John EM, Miron A, Grenaker Alnaes G, Kristensen V, Borresen-Dale AL, Giles GG, Baglietto L, McLean CA, Severi G, Kosel ML, Pankratz VS, Slager S, Olson JE, Radice P, Peterlongo P, Manoukian S, Barile M, Lambrechts D, Hatse S, Dieudonne AS, Christiaens MR, Chenevix-Trench G, Investigators K, Group A, Beesley J, Chen X, Mannermaa A, Kosma VM, Hartikainen JM, Soini Y, Easton DF, Couch FJ.

19p13.1 is a triple negative-specific breast cancer susceptibility locus.

Cancer Res. 2012 Feb 13.

  1.  

Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators.

Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.

N Engl J Med. 2012 Feb 16;366(7):601-9.

  1.  

Pentheroudakis G, Nicolaou I, Kotoula V, Fountzilas E, Markou K, Eleftheraki AG, Fragkoulidi A, Karasmanis I, Tsigka A, Angouridakis N, Vlachtsis K, Nikolaou A, Pavlidis N, Fountzilas G.

Prognostic utility of angiogenesis and hypoxia effectors in patients with operable squamous cell cancer of the larynx.

Oral Oncol. 2012 Feb 25.

  1.  

Fostira F, Tsitlaidou M, Papadimitriou C, Pertesi M, Timotheadou E, Stavropoulou AV, Glentis S, Bournakis E, Bobos M, Pectasides D, Papakostas P, Pentheroudakis G, Gogas H, Skarlos P, Samantas E, Bafaloukos D, Kosmidis PA, Koutras A, Yannoukakos D, Konstantopoulou I, Fountzilas G.

Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.

Breast Cancer Res Treat. 2012 Mar 21

  1.  

Stoyianni A, Goussia A, Pentheroudakis G, Siozopoulou V, Ioachim E, Krikelis D, Golfinopoulos V, Cervantes A, Bobos M, Fotsis T, Bellou S, Fountzilas G, Malamou-Mitsi V, Pavlidis N.

Immunohistochemical study of the epithelial-mesenchymal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utility.

Anticancer Res. 2012 Apr;32(4):1273-81.

  1.  

Krikelis D, Pentheroudakis G, Goussia A, Siozopoulou V, Bobos M, Petrakis D, Stoyianni A, Golfinopoulos V, Cervantes A, Ciuleanu T, Fountzilas G, Malamou-Mitsi V, Pavlidis N.

Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary.

Clin Exp Metastasis. 2012 Aug;29(6):603-14. Epub 2012 Apr 19.

  1.  

Golfinopoulos V, Pentheroudakis G, Goussia A, Siozopoulou V, Bobos M, Krikelis D, Cervantes A, Ciuleanu T, Marselos M, Fountzilas G, Malamou-Mitsi V, Pavlidis N.

Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a study of 100 CUP cases.

Ann Oncol. 2012 May 6.

  1.  

Razis E, Kalogeras KT, Kotoula V, Eleftheraki AG, Nikitas N, Kronenwett R, Timotheadou E, Christodoulou C, Pectasides D, Gogas H, Wirtz RM, Makatsoris T, Bafaloukos D, Aravantinos G, Televantou D, Pavlidis N, Fountzilas G.

Improved Outcome of High-Risk Early HER2 Positive Breast Cancer With High CXCL13-CXCR5 Messenger RNA Expression.

Clin Breast Cancer. 2012 Jun;12(3):183-93.

  1.  

Fountzilas G, Dafni U, Bobos M, Batistatou A, Kotoula V, Trihia H, Malamou-Mitsi V, Miliaras S, Chrisafi S, Papadopoulos S, Sotiropoulou M, Filippidis T, Gogas H, Koletsa T, Bafaloukos D, Televantou D, Kalogeras KT, Pectasides D, Skarlos DV, Koutras A, Dimopoulos MA.

Differential Response of Immunohistochemically Defined Breast Cancer Subtypes to Anthracycline-Based Adjuvant Chemotherapy with or without Paclitaxel.

PLoS One. 2012;7(6):e37946.

  1.  

Pectasides D, Papaxoinis G, Kalogeras KT, Eleftheraki AG, Xanthakis I, Makatsoris T, Samantas E, Varthalitis I, Papakostas P, Nikitas N, Papandreou CN, Pentheroudakis G, Timotheadou E, Koutras A, Sgouros J, Bafaloukos D, Klouvas G, Economopoulos T, Syrigos KN, Fountzilas G.

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.

BMC Cancer. 2012 Jun 29;12:271.

  1.  

Kotoula V, Krikelis D, Karavasilis V, Koletsa T, Eleftheraki AG, Televantou D, Christodoulou C, Dimoudis S, Korantzis I, Pectasides D, Syrigos KN, Kosmidis PA, Fountzilas G.

Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).

BMC Cancer. 2012 Aug 6;12:342.

  1.  

Murray S, Karavasilis V, Bobos M, Razis E, Papadopoulos S, Christodoulou C, Kosmidis P, Fountzilas G. Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer.

J Exp Clin Cancer Res. 2012 Sep 19;31(1):77.

  1.  

Korantzis I, Kalogeras KT, Papaxoinis G, Kotoula V, Koutras A, Soupos N, Papakostas P, Dionysopoulos D, Samantas E, Christodoulou C, Linardou H, Pectasides D, Fountzilas G.

Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel.

Anticancer Res. 2012 Oct;32(10):4569-80.

  1.  

Fragoulakis V, Papagiannopoulou V, Kourlaba G, Maniadakis N, Fountzilas G.

Cost-minimization analysis of the treatment of patients with metastatic colorectal cancer in Greece.

Clin Ther. 2012 Oct;34(10):2132-42.

  1.  

Panagopoulou P, Gogas H, Dessypris N, Maniadakis N, Fountzilas G, Petridou ET.

Survival from breast cancer in relation to access to tertiary healthcare, body mass index, tumor characteristics and treatment: a Hellenic Cooperative Oncology Group (HeCOG) study.

Eur J Epidemiol. 2012 Nov;27(11):857-66.

  1.  

Fountzilas G, Christodoulou C, Bobos M, Kotoula V, Eleftheraki AG, Xanthakis I, Batistatou A, Pentheroudakis G, Xiros N, Papaspirou I, Koumarianou A, Papakostas P, Bafaloukos D, Skarlos DV, Kalogeras KT.

Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.

J Transl Med. 2012 Oct 23;10:212. doi: 10.1186/1479-5876-10-212.

  1.  

Pliarchopoulou K, Kalogeras KT, Kronenwett R, Wirtz RM, Eleftheraki AG, Batistatou A, Bobos M, Soupos N, Polychronidou G, Gogas H, Samantas E, Christodoulou C, Makatsoris T, Pavlidis N, Pectasides D, Fountzilas G.

Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.

Cancer Chemother Pharmacol. 2012 Oct 25. [Epub ahead of print]

  1.  

Pentheroudakis G, Spector Y, Krikelis D, Kotoula V, Meiri E, Malamou-Mitsi V, Fountzilas G, Sanden M, Pavlidis N, Benjamin H, Aharonov R.

Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors.

Clin Exp Metastasis. 2012 Nov 4. [Epub ahead of print]

  1.  

Bamias A, Dafni U, Karadimou A, Timotheadou E, Aravantinos G, Psyrri A, Xanthakis I, Tsiatas M, Koutoulidis V, Constantinidis C, Hatzimouratidis C, Samantas E, Visvikis A, Chrisophos M, Stravodimos K, Deliveliotis C, Eleftheraki A, Pectasides D, Fountzilas G, Dimopoulos MA.

Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03).

Ann Oncol. 2012 Nov 7. [Epub ahead of print]

  1.  

Linardou H, Kalogeras KT, Kronenwett R, Kouvatseas G, Wirtz RM, Zagouri F, Gogas H, Christodoulou C, Koutras AK, Samantas E, Pectasides D, Bafaloukos D, Fountzilas G.

The prognostic and predictive value of mRNA expression of VEGF family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.

Breast Cancer Res. 2012 Nov 12;14(6):R145. [Epub ahead of print]

  1.  

Nikitas N, Karadimou A, Tsitoura E, Soupos N, Tsiatas M, Karavasilis V, Pectasides D, Pavlidis N, Chrisofos M, Adamakis I, Murray S, Fountzilas G, Dimopoulos MA, Bamias A.

Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group study.

Pharmacogenomics. 2012 Nov;13(14):1595-607.

  1.  

Televantou D, Karkavelas G, Hytiroglou P, Lampaki S, Iliadis G, Selviaridis P, Polyzoidis KS, Fountzilas G, Kotoula V.

DARPP32, STAT5 and STAT3 mRNA Expression Ratios in Glioblastomas are Associated with Patient Outcome.

Pathol Oncol Res. 2012 Dec 20. [Epub ahead of print]

  1.  

Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research.

Kotoula V, Kalogeras KT, Kouvatseas G, Televantou D, Kronenwett R, Wirtz RM, Fountzilas G.

Virchows Arch. 2013 Feb;462(2):141-54.

  1.  

A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.

Karavasilis V, Kotoula V, Pentheroudakis G, Televantou D, Lambaki S, Chrisafi S, Bobos M, Fountzilas G.

J Neurol. 2013 Jan 5. [Epub ahead of print]

  1.  

Revising the Radiobiological Model of Synchronous Chemotherapy in Head-and-Neck Cancer: A New Analysis Examining Reduced Weighting of Accelerated Repopulation.

Meade S, Sanghera P, McConkey C, Fowler J, Fountzilas G, Glaholm J, Hartley A.

Int J Radiat Oncol Biol Phys. 2013 Jan 16. doi:pii: S0360-3016(12)03820-5. 10.1016/j.ijrobp.2012.11.023. [Epub ahead of print]

  1.  

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.

Martin V, Landi L, Molinari F, Fountzilas G, Geva R, Riva A, Saletti P, De Dosso S, Spitale A, Tejpar S, Kalogeras KT, Mazzucchelli L, Frattini M, Cappuzzo F.

Br J Cancer. 2013 Jan 24. doi: 10.1038/bjc.2013.4. [Epub ahead of print]

  1.  

Psychiatric manifestations, personality traits and health-related quality of life in cancer of unknown primary site.

Hyphantis T, Papadimitriou I, Petrakis D, Fountzilas G, Repana D, Assimakopoulos K, Carvalho AF, Pavlidis N.

Psychooncology. 2013 Jan 29. doi: 10.1002/pon.3244. [Epub ahead of print]

  1.  

Expression profiling of 21 biomolecules in locally advanced nasopharyngeal carcinomas of Caucasian patients.

Krikelis D, Bobos M, Karayannopoulou G, Resiga L, Chrysafi S, Samantas E, Andreopoulos D, Vasiliou V, Ciuleanu E, Fountzilas G.

BMC Clin Pathol. 2013 Jan 29;13:1. doi: 10.1186/1472-6890-13-1.

  1.  

Insulin-Like Growth Factor 1 Receptor (IGF1R) Expression and Survival in Operable Squamous-Cell Laryngeal Cancer.

Mountzios G, Kostopoulos I, Kotoula V, Sfakianaki I, Fountzilas E, Markou K, Karasmanis I, Leva S, Angouridakis N, Vlachtsis K, Nikolaou A, Konstantinidis I, Fountzilas G.

PLoS One. 2013;8(1):e54048. doi: 10.1371/journal.pone.0054048.

  1.  
  1.  

Cyclin D1, EGFR, and Akt/mTOR pathway: Potential prognostic markers in localized laryngeal squamous cell carcinoma.

Dionysopoulos D, Pavlakis K, Kotoula V, Fountzilas E, Markou K, Karasmanis I, Angouridakis N, Nikolaou A, Kalogeras KT, Fountzilas G.

Strahlenther Onkol. 2013 Feb 13.

  1.  

Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype.

Rampias T, Pectasides E, Prasad M, Sasaki C, Gouveris P, Dimou A, Kountourakis P, Perisanidis C, Burtness B, Zaramboukas T, Rimm D, Fountzilas G, Psyrri A.

Ann Oncol. 2013 Feb 13.

  1.  

Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, Kafiri G, Tsamandas AC, Razis E, Galani E, Bafaloukos D, Efstratiou I, Bompolaki I, Pectasides D, Pavlidis N, Tejpar S, Fountzilas G.

mRNA expression of Egfr ligands and mutational profiling of the RAS/RAF, pI3K pathways in cetuximab-treated patients with advanced colorectal cancer

BMC in press

  1.  

Fountzilas G, Kotoula V, Pectasides D, Kouvatseas G, Timotheadou E, Bobos M, Mavropoulou X, Papadimitriou C, Vrettou E, Raptou G, Koutras A, Razis E, Bafaloukos D, Samantas E, Pentheroudakis G, Skarlos DV

Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; A randomized non-comparative phase II trial.

PLoS one, to be revised

 

 

 

Κύριο Μενού

 
ΓΕΝΙΚΟ ΝΟΣΟΚΟΜΕΙΟ ΠΑΠΑΓΕΩΡΓΙΟΥ - TK 56403 - ΘΕΣΣΑΛΟΝΙΚΗ - ΠΕΡΙΦΕΡΕΙΑΚΗ ΟΔΟΣ - ΔΗΜΟΣ ΠΑΥΛΟΥ ΜΕΛΑ (ΠΕΡΙΟΧΗ Ν. ΕΥΚΑΡΠΙΑ)
T: 2313 323000